Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

Orazio Caffo, Gaetano Facchini, Elisa Biasco, Francesco Ferraù, Franco Morelli, Maddalena Donini, Consuelo Buttigliero, Nicola Calvani, Annalisa Guida, Vincenzo Emanuele Chiuri, Umberto Basso, Claudia Mucciarini, Vincenza Conteduca, Sabrina Rossetti, Antonello Veccia, Francesca Maines, Stefania Kinspergher, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.

RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.

CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.

Original languageEnglish
JournalFuture Oncology
DOIs
Publication statusPublished - Mar 19 2019

Fingerprint

Castration
Cyclophosphamide
Prostatic Neoplasms
Safety
docetaxel
Disease-Free Survival
Survival
Therapeutics

Cite this

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. / Caffo, Orazio; Facchini, Gaetano; Biasco, Elisa; Ferraù, Francesco; Morelli, Franco; Donini, Maddalena; Buttigliero, Consuelo; Calvani, Nicola; Guida, Annalisa; Chiuri, Vincenzo Emanuele; Basso, Umberto; Mucciarini, Claudia; Conteduca, Vincenza; Rossetti, Sabrina; Veccia, Antonello; Maines, Francesca; Kinspergher, Stefania; De Giorgi, Ugo.

In: Future Oncology, 19.03.2019.

Research output: Contribution to journalArticle

Caffo, O, Facchini, G, Biasco, E, Ferraù, F, Morelli, F, Donini, M, Buttigliero, C, Calvani, N, Guida, A, Chiuri, VE, Basso, U, Mucciarini, C, Conteduca, V, Rossetti, S, Veccia, A, Maines, F, Kinspergher, S & De Giorgi, U 2019, 'Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer', Future Oncology. https://doi.org/10.2217/fon-2018-0715
Caffo, Orazio ; Facchini, Gaetano ; Biasco, Elisa ; Ferraù, Francesco ; Morelli, Franco ; Donini, Maddalena ; Buttigliero, Consuelo ; Calvani, Nicola ; Guida, Annalisa ; Chiuri, Vincenzo Emanuele ; Basso, Umberto ; Mucciarini, Claudia ; Conteduca, Vincenza ; Rossetti, Sabrina ; Veccia, Antonello ; Maines, Francesca ; Kinspergher, Stefania ; De Giorgi, Ugo. / Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. In: Future Oncology. 2019.
@article{2d3c4673afd24a7e83372ed5e162730d,
title = "Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer",
abstract = "AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.",
author = "Orazio Caffo and Gaetano Facchini and Elisa Biasco and Francesco Ferra{\`u} and Franco Morelli and Maddalena Donini and Consuelo Buttigliero and Nicola Calvani and Annalisa Guida and Chiuri, {Vincenzo Emanuele} and Umberto Basso and Claudia Mucciarini and Vincenza Conteduca and Sabrina Rossetti and Antonello Veccia and Francesca Maines and Stefania Kinspergher and {De Giorgi}, Ugo",
year = "2019",
month = "3",
day = "19",
doi = "10.2217/fon-2018-0715",
language = "English",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

AU - Caffo, Orazio

AU - Facchini, Gaetano

AU - Biasco, Elisa

AU - Ferraù, Francesco

AU - Morelli, Franco

AU - Donini, Maddalena

AU - Buttigliero, Consuelo

AU - Calvani, Nicola

AU - Guida, Annalisa

AU - Chiuri, Vincenzo Emanuele

AU - Basso, Umberto

AU - Mucciarini, Claudia

AU - Conteduca, Vincenza

AU - Rossetti, Sabrina

AU - Veccia, Antonello

AU - Maines, Francesca

AU - Kinspergher, Stefania

AU - De Giorgi, Ugo

PY - 2019/3/19

Y1 - 2019/3/19

N2 - AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.

AB - AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.

U2 - 10.2217/fon-2018-0715

DO - 10.2217/fon-2018-0715

M3 - Article

C2 - 30887825

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -